<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00527449</url>
  </required_header>
  <id_info>
    <org_study_id>3305000</org_study_id>
    <nct_id>NCT00527449</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Chemotherapy of Primary Breast Cancer With Epirubicin/Docetaxel and Carboplatin/Docetaxel</brief_title>
  <acronym>ETCat01</acronym>
  <official_title>Neoadjuvant Chemotherapy With 3x Epirubicin/Docetaxel Followed by 3x Carboplatin/Docetaxel in Patients With Primary Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Klinikum Weissenfels</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Klinikum Weissenfels</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to optimize results in neoadjuvant chemotherapy of local
      advanced primary breast cancer. Therefore patients become first 3 cycles of
      Epirubicin/Docetaxel followed by 3x Carboplatin/Docetaxel.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Most of the women who are diagnosed with breast cancer are in the situation that an operation
      is possible. Using a neoadjuvant therapy the rate of breast-conserving surgery can be
      extended and tumor cell proliferation may be inhibited. Further the neoadjuvant chemotherapy
      is an in-vivo-activity-test for the used drugs. Epirubicin, Docetaxel and Carboplatin have
      shown antineoplastic activity against solid cancer alone and in combination.

      Using two different combinations of these three drugs, first 3 cycles Epirubicin/Docetaxel
      and then changing to Carboplatin/Docetaxel for 3 further cycles it is assumed that the
      results of the therapy will improve. Main criterion is the determination of pCR, second
      criteria are the rate of breast-conserving surgery, tumor response and therapy-dependent
      toxicities.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determining pathologic complete remission under study treatment</measure>
    <time_frame>28 days after last administration of chemotherapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of breast conserving operations</measure>
    <time_frame>28 days after administration of last chemotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to treatment</measure>
    <time_frame>28 days after last administration of chemotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determining the therapy associated toxicity</measure>
    <time_frame>28 days after last administration of chemotherapy</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">50</enrollment>
  <condition>Primary Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin, Carboplatin, Docetaxel</intervention_name>
    <description>75 mg/m² Docetaxel (60 minutes i.v.) and 90 mg/m² Epirubicin (10-15 min i.v.) on day 1, 22, 42. After these 3 cycles 75 mg/m² Docetaxel (60 minutes i.v.) and Carboplatin AUC 5 (30 min i. v.) on day 63, 84, 105.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically assured breast cancer

          -  age &gt;= 18 years

          -  bone marrow function: neutrophils &gt;= 1.5x109/l, platelets &gt;= 100x109/l, hemoglobin
             &gt;=6.2 mmol/l

          -  sufficient renal and liver function

          -  ECOG 0-2

          -  written informed consent

        Exclusion Criteria:

          -  pregnant or nursing women

          -  distant metastases

          -  T2-Tumour &lt; 3cm and G1

          -  existing motoric or sensoric neurotoxicity &gt; Grade 2

          -  known hypersensitivity against Epirubicin or other anthracycline or against
             Carboplatin or other platin derivatives or against Docetaxel or against substances in
             the preparing solutions
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dieter Lampe, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asklepios Krankenhaus Weissenfels</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Krankenhaus St. Elisabeth u. St. Barbara</name>
      <address>
        <city>Halle</city>
        <state>Sachsen-Anhalt</state>
        <zip>06110</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Marienstift</name>
      <address>
        <city>Magdeburg</city>
        <state>Sachsen-Anhalt</state>
        <zip>39110</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Krankenhaus Weissenfels</name>
      <address>
        <city>Weissenfels</city>
        <state>Sachsen-Anhalt</state>
        <zip>06667</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2007</study_first_submitted>
  <study_first_submitted_qc>September 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2007</study_first_posted>
  <last_update_submitted>January 14, 2010</last_update_submitted>
  <last_update_submitted_qc>January 14, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 15, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dieter Lampe, Dr. med.</name_title>
    <organization>Klinikum Weissenfels</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

